Alector, Inc. (ALEC)

Market Cap	182.15M
Revenue (ttm)	61.51M
Net Income (ttm)	-158.41M
Shares Out	97.93M
EPS (ttm)	-1.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,735,399
Open	1.760
Previous Close	1.780
Day's Range	1.725 - 1.885
52-Week Range	1.725 - 8.900
Beta	0.51
Analysts	Buy
Price Target	11.75 (+531.72%)
Earnings Date	Nov 6, 2024

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The compa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 7, 2019
• Employees: 244
• Stock Exchange: NASDAQ
• Ticker Symbol: ALEC
• Website: https://www.alector.com

Financial Performance

In 2023, Alector's revenue was $97.06 million, a decrease of -27.36% compared to the previous year's $133.62 million. Losses were -$130.39 million, -2.19% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ALEC stock is "Buy." The 12-month stock price forecast is $11.75, which is an increase of 531.72% from the latest price.

Price Target

$11.75

(531.72% upside)

Analyst Consensus: Buy